OnabotulinumtoxinA for Systemic Sclerosis-associated Raynaud's Phenomenon: A Multi-Institutional Study on Accessibility and Effectiveness

被引：1
|
作者：
Kassamali, Bina [1 ,2 ]
Desai, Sheena [1 ,3 ]
Min, Michelle S. [1 ,2 ]
Mazori, Daniel R. [1 ,2 ]
Villa-Ruiz, Camila [1 ,4 ]
Kus, Kylee J. B. [1 ,5 ]
Cobos, Gabriela A. [1 ,2 ]
Merola, Joseph [1 ,2 ,6 ]
LaChance, Avery [1 ,2 ]
Vleugels, Ruth Ann [1 ,2 ]
机构：
[1] Brigham & Womens Hosp, Dept Dermatol, Boston, MA 02115 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Tufts Univ, Sch Med, Boston, MA USA
[4] Ponce Hlth Sci Univ, Sch Med, Ponce, Peoples R China
[5] Oakland Univ, William Beaumont Sch Med, Rochester, MI USA
[6] Brigham & Womens Hosp, Div Rheumatol, Dept Med Immunol & Allergy, Boston, MA USA
来源：
JOURNAL OF DRUGS IN DERMATOLOGY | 2021年 / 20卷 / 11期
关键词：
BOTULINUM-TOXIN;
D O I：
10.36849/JDD.6135
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
[No abstract available]
引用
收藏
页码：1257 / 1259
页数：3
相关论文
共 50 条
  • [31] EFFICACY OF AMINAFTONE IN THE TREATMENT OF RAYNAUD'S PHENOMENON IN PATIENTS WITH SYSTEMIC SCLEROSIS: A PRELIMINARY STUDY
    Parisi, S.
    Scarati, M.
    Bruzzone, M.
    Lagana, A.
    Peroni, C. L.
    Fusaro, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 654 - 654
  • [32] Preliminary Assessment of Internal Reliability and Construct Validity of Long and Short-form Assessment of Systemic Sclerosis-associated RAynaud's Phenomenon (ASRAP) Questionnaires
    Pauling, John
    Yu, Lan
    Denton, Christopher
    Frech, Tracy
    Herrick, Ariane
    Hummers, Laura
    Saketkoo, Lesley Ann
    Shah, Ami
    Khanna, Dinesh
    Domsic, Robyn
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 1035 - 1036
  • [33] TAKO-TSUBO CARDIOMYOPATHY ASSOCIATED WITH SYSTEMIC SCLEROSIS: A SIGN OF MYOCARDIAL RAYNAUD'S PHENOMENON?
    Goff, Iain
    Reynolds, Gary
    Grove, Matthew
    RHEUMATOLOGY, 2013, 52 : 62 - 63
  • [34] COMPARISON OF POSTOCCLUSIVE HYPEREMIA IN SYSTEMIC SCLEROSIS AND PRIMARY RAYNAUD'S PHENOMENON
    Gaillard-Bigot, F.
    Roustit, M.
    Blaise, S.
    Gabin, M.
    Cracowski, C.
    Seinturier, C.
    Imbert, B.
    Carpentier, P.
    Cracowski, J. L.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (02) : S74 - S74
  • [35] Efficacy of cilostazol for the treatment of Raynaud's phenomenon in systemic sclerosis patients
    Negrini, Simone
    Spano, Francesca
    Penza, Elena
    Rollando, Daniela
    Indiveri, Francesco
    Filaci, Gilberto
    Puppo, Francesco
    CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 16 (03) : 407 - 412
  • [36] Pathophysiology and clinical consequences of Raynaud's phenomenon related to systemic sclerosis
    Sunderkoetter, C.
    Riemekasten, G.
    RHEUMATOLOGY, 2006, 45 : 33 - 35
  • [37] Neuronal Regulators and Vascular Dysfunction in Raynaud's Phenomenon and Systemic Sclerosis
    Fonseca, Carmen
    Abraham, David
    Ponticos, Markella
    CURRENT VASCULAR PHARMACOLOGY, 2009, 7 (01) : 34 - 39
  • [38] The clinical relevance of Raynaud's phenomenon symptom characteristics in systemic sclerosis
    Hughes, Michael
    Huang, Suiyuan
    Pauling, John D.
    Sabbagh, Maya
    Khanna, Dinesh
    CLINICAL RHEUMATOLOGY, 2022, 41 (10) : 3049 - 3054
  • [39] Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis
    Thompson, AE
    Shea, B
    Welch, V
    Fenlon, D
    Pope, JE
    ARTHRITIS AND RHEUMATISM, 2001, 44 (08): : 1841 - 1847
  • [40] Treatment of severe Raynaud's phenomenon with bosentan in a patient with systemic sclerosis
    Dunne, J.
    Dutz, J.
    Shojania, K.
    Ng, B.
    van Eeden, S.
    RHEUMATOLOGY, 2006, 45 (07) : 911 - 912
12345